The proportion of foreign sales (exports) of the top 10 traditional pharmaceutical companies in Korea was found to be taking a step back. What was 11% in 2017 has dropped to 8% in the last 2-3 years.
The percentage of foreign sales is a barometer that can measure the level of globalization and development of the domestic pharmaceutical industry. Korea is in a situation where domestic demand is limited and overseas sales must be generated.
Share of foreign sales (amount of foreign sales ÷ total sales × 100) among the sales revenue of the top 10 traditional pharmaceutical companies in the first quarter of this year, 2022, and 2021 [표 1]calculated as
For foreign sales, external audit data disclosed in the Financial Supervision Service DART Ⅱ. Business content 4. In the case of consolidated performance where there is no ‘separate’ clue to sales performance, it was deemed that it would have been adjusted at the time of consolidation of financial statements, so only exports were considered as foreign sales. In case of , the sales of subsidiaries whose locations are abroad are included in exports and are considered foreign sales.
[표 1], the percentage of foreign sales of 10 leading traditional pharmaceutical companies was 8.2% in the first quarter of this year. Last year, 2022 was 7.6%, and the year before last, 7.7% in 2021, so it seems that it can be seen as an improving trend.
To check if this trend judgment is correct, the following [표 2]I tried to extend the judgment period much more this way. Judging the improvement trend was just an optical illusion. Seven years ago, the share of foreign sales in 2017 was 10.6%, 10.0% in 2018, and 9.2% in 2019, much higher than recently.
What about Japan, which pioneered the global market early? Data from 10 representative pharmaceutical companies from Japan (有便考动美国) are as follows [표 3]I tried to extract it and analyze it as follows.
The overseas sales share of Japan’s top 10 pharmaceutical companies was 57.2% in 2022 and 54.5% in 2021. It was found to be about 7 times higher than ours.
At the end of March 2022, Takeda posted 28,628 billion won, or 81.5%, of its total sales revenue of 35,111.1 billion won (applying 9.8378 won to 1 yen) from overseas, and Otsuka At the end of December 2022, HD) also earned 10.6573 trillion won from overseas, accounting for 62.3% of its total sales of 17.981 trillion won.
Astellas foreign sales account for 79.3%, Chugai 30.5%, Daiichi Sankyo 46.6%, Esai 51.4%, and Sumitomo Pharma 51.4%. ) 60.2%, Ono 33.0%, Kyowa Kirin 61.2%, and Shionogi 66′. 0.9% to 17.9% of GS Green Cross, which is the highest,’ it’s a difference between heaven and earth.
Why did this result happen? Could it be that the ‘importance of overseas marketing and sales’ has been pushed to the back of other tasks?
Today, 70 to 80 years have passed since Japan’s colonial period, which was a period of encumbrances, and the 6/25 massacre was noted as the cause of Korea’s general hindsight. (惡緣)’ cannot be the reason.
It is clear that the globalization of the Korean traditional pharmaceutical industry cannot be expected unless the share of foreign sales of the main Korean traditional pharmaceutical companies deviates significantly from the current level (8%).